» Articles » PMID: 38573364

Takotsubo Cardiomyopathy in Guillain-Barré Syndrome

Abstract

Background And Purpose: Takotsubo cardiomyopathy (TCM) is a serious autonomic complication of Guillain-Barré syndrome (GBS). However, the association between TCM and GBS has not been investigated in detail. We investigated the characteristics of GBS patients with TCM (GBS-TCM).

Methods: Clinical features and anti-ganglioside antibody between the GBS-TCM patients and 62 classical GBS patients without TCM as control patients were compared.

Results: Eight GBS-TCM patients were identified, in whom TCM was diagnosed at a mean of 6.5 [range 3-42] days after the onset of GBS. The age at onset of GBS was elder in the GBS-TCM patients than in the control GBS patients (76.5 [56-87] vs. 52 [20-88] years, p < 0.01). Notably, cranial nerve deficits, particularly in the lower cranial nerves, were observed in all GBS-TCM patients (100% vs. 41.9%, p < 0.01). Additionally, the GBS-TCM patients showed a higher GBS disability score at nadir (5 [4-5] vs. 4 [1-5], p < 0.01), and lower Medical Research Council sum scores at admission and nadir (37 [30-44] vs. 48 [12-60] at admission, p < 0.05, and 20 [12-44] vs. 40 [0-60] at nadir, p < 0.05, respectively). Mechanical ventilation was more frequently required in the GBS-TCM patients (62.5% vs. 11.3%, p < 0.01). Three GBS-TCM patients were positive for anti-ganglioside antibodies.

Conclusions: TCM occurred at a relatively early phase of GBS. The characteristics of GBS-TCM were the elder, lower cranial nerve involvements, severe limb weakness, and respiratory failure.

Citing Articles

Takotsubo cardiomyopathy associated with free wall rupture and ventricular septal defect: a case report.

Hassanabad A, Sembo T, Kidd W, Har B Future Cardiol. 2024; 20(10):543-546.

PMID: 39101463 PMC: 11485990. DOI: 10.1080/14796678.2024.2382541.

References
1.
Leonhard S, Mandarakas M, Gondim F, Bateman K, Ferreira M, Cornblath D . Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019; 15(11):671-683. PMC: 6821638. DOI: 10.1038/s41582-019-0250-9. View

2.
van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs B, van Doorn P . Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014; 10(8):469-82. DOI: 10.1038/nrneurol.2014.121. View

3.
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn P, Jacobs B . Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2013; 137(Pt 1):33-43. DOI: 10.1093/brain/awt285. View

4.
Kusunoki S, Willison H, Jacobs B . Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. J Neurol Neurosurg Psychiatry. 2020; 92(3):311-318. DOI: 10.1136/jnnp-2020-325053. View

5.
Sejvar J, Kohl K, Gidudu J, Amato A, Bakshi N, Baxter R . Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2010; 29(3):599-612. DOI: 10.1016/j.vaccine.2010.06.003. View